US and European Radiopharmaceuticals Industry

• Publication date: October 2011

This report analyzes the US and the European markets for Radiopharmaceuticals in US$ Million by the following Product Segments: Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets.The report profiles 65 companies including many key and niche players such as Actinium Pharmaceuticals, Inc.,...

This report analyzes the US and the European markets for Radiopharmaceuticals in US$ Million by the following Product Segments: Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets.The report profiles 65 companies including many key and niche players such as Actinium Pharmaceuticals, Inc., Advanced Medical Isotope Corporation, Alseres Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals, Bio-Nucleonics, Inc., Bracco Diagnostics, Inc., Cardinal Health, Inc., Cellectar, LLC., Cell Therapeutics, Inc., Covidien Imaging Solutions, EUSA Pharma (Europe) Ltd., Jubilant DraxImage Inc., GE Healthcare Limited, GlaxoSmithKline Plc, IBA Group, Immunomedics, Inc., Lantheus Medical Imaging, Inc, Nordion, Molecular Insight Pharmaceuticals, Inc., Novelos Therapeutics Inc., Peregrine Pharmaceuticals, Inc., PETNET Pharmaceuticals, Inc., Pharmalucence, Inc., Spectrum Pharmaceuticals, Inc., and Triad Isotopes, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Medical Imaging Industry in the United Kingdom

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
A. Diagnostic Radiopharmaceuticals 4
B. Therapeutic Radiopharmaceuticals 4

2. INDUSTRY OVERVIEW 5
A Quick Primer 5
Market Scenario: A Review 5
Recession Impact in Retrospect 5
Outlook 6
Key Market Trends 7
Continuous Battle Against Cancer: A Key Driver for Growth 7
Cancer Statistics: A Grim Prognosis 7
Business Case for Radiopharmaceuticals Exemplified 7
Development of Newer Diagnostic Agents to Boost Growth 7
Emergence of Radioisotope Based Personalized Therapy 8
Demographics & New Applications Offer Opportunities On a Platter 8
Recognition of Intrinsic Cost Benefits: Critical to Market
Acceptance 8
Widespread Awareness Among Practitioners & Patients: The Need
of the Hour 9
Expansion of Molecular Imaging Platform is Key to Future Growth 9
Molecular Imaging Agents: A Noteworthy Breakthrough 9
Growing Demand for PET to Drive Up Demand 10
Introduction of SPECT/CT & PET/CT: Double Edged Weapons for
Growth 10
Manufacturers Quick to Take Cue 11
Promising Developments in Therapeutic Radiopharmaceuticals
Underway 11
Targeted Peptides & Alpha Emitters: The New Frontiers of
Therapeutic Radiopharmaceuticals 12
International Collaborations Give a Thumbs Up to Drug
Development 12
Market Challenges 12
High Costs of Drug Development Piques Manufacturers 12
Supply Shortages: A Niggling Cause of Concern 13
Table 1: Worldwide Market for 99Mo (2010): Percentage Share
Breakdown of Weekly Demand by Region (includes corresponding
Graph/Chart) 14

Table 2: Worldwide Market for 99Mo (2010): Percentage Share
Breakdown of Production by Reactor (includes corresponding
Graph/Chart) 14
Price Sensitivity & Competition from Alternatives Limit
Market Potential 14
Lack of Dosage Standards for Pediatric Patients’ Limits
Radiopharmaceutical Efficacy 15
Unfounded Fears of Radiation Exposure Hinder Growth 15
Bottlenecks in Developing Markets 15

3. PRODUCT OVERVIEW 16
Nuclear Medicine: A Prelude 16
Radiopharmaceuticals: A Definition 16
Mechanism of Action 16
Application of Radiopharmaceuticals 17
Classification of Radiopharmaceuticals 17
Diagnostic Radiopharmaceuticals 17
Commonly Used Diagnostic Radiopharmaceutical Agents 18
Major Isotopes and their Diagnostic Applications 18
Advantages 19
Classification 19
Fluorodeoxy Glucose (FDG): A Rapidly Growing Diagnostic
Radiopharmaceutical 20
Molecular Imaging Modalities In Radiopharmaceutical Diagnostics 20
Planar Imaging 20
PET: A Prime Growth Driver for FDG 20
Advantages 21
Applications of PET 21
Commonly used Radioisotopes in PET Scans 22
Major PET Isotopes and their Applications 22
Single Photon Emission Computed Tomography (SPECT) 23
Applications of SPECT 23
Commonly used Radioisotopes in SPECT Scans 24
Therapeutic Radiopharmaceuticals 24
Characteristics of Therapeutic Radiopharmaceuticals 24
Commonly used Therapeutic Agents 25
Major Isotopes and their Therapeutic Applications 25
Radiopharmaceuticals for Thyroid Therapy 25
Radiopharmaceuticals for Cancer Therapy 25
Radiopharmaceuticals for Radiosynoviorthesis Therapy 26
Radiopharmaceuticals for Bone Pain Palliation Therapy 26
Radiopharmacy: A Key Link in the Distribution Chain 26
Table 3: US Radiopharmacies Market (2010): Percentage Share
Breakdown of SPECT Doses Sold by Company (includes
corresponding Graph/Chart) 27

4. PRODUCT INNOVATIONS/INTRODUCTIONS 28
Positron to Launch PosiRx 28
Positron to Develop Indium Oxine 28
GE Healthcare Enhances Radiopharmaceuticals Product Portfolio 28
IBA Molecular Obtains Positive Opinion to Market Dopacis in
Europe 29
Bhabha Atomic Research Centre Develops Radiopharmaceuticals
for Cancer Treatment 29
Medrad Mounts Intego™ PET Infusion System at UPMC 30
IBA Molecular Announces the Launch of Cyclone ® 18 Twin 30
Immunomedics Announces Pre-Clinical Results for its
Combination Radioimmunotherapy 30
Molecular Insight Develops New Radioiodinated Molecules 30
Immunomedics Develops New Antibody for Radioimmunotherapy 30

5. RECENT INDUSTRY ACTIVITY 31
Novelos Therapeutics Pockets Cellectar Inc 31
Southern Research Institute Inks Agreement with Biomedical
Research Foundation 31
IBA Acquires Minority Stake in PET Net Solutions 32
Covidien Enters into Agreement with IAE POLATOM 32
Dalat Nuclear Research Institute Inks Agreement with
Probactive Biotech 32
Principio Wins Licensing Agreement from Johns Hopkins Sidney
Kimmel Comprehensive Cancer Center 33
Covidien Inks Definitive Agreement with Triad Isotopes 33
Eli Lilly Inks Merger Agreement with Avid Radiopharmaceuticals 33
Lumiphore Inks Agreement with Algeta 33
IBA Renews Contract with Servicio Andaluz de Salud 34
Lumiphore and Algeta Ink Partnership Agreement 34
Positron and Covidien Ink Agreement 35
PETNET Solutions Expands PET Radiopharmaceutical Network 35
Triad Isotopes Acquires Radiopharmacy Network of Covidien 35
Principio Receives Exclusive Technological Development License
from Hopkins Sidney Kimmel Comprehensive Cancer Center 36
PETNET Solutions Renews Supply Agreement with Paul Strickland
Scanner Centre 36
IBA Molecular Obtains Marketing Approval for Filtracis
Radiopharmaceutical Kit 36
DHA Inks MoU with DCD 36
Algeta Signs Agreement with Bayer 37
TAEK to Establish Proton Accelerator Facility 37
Antisoma Collaborates with Bryan Oncor 37
Karpov Institute Enters into Collaboration with MDS Nordion 38
MDS Nordion Establishes Glucotrace Facility 38
Draximage Inks Agreement with Guerbet 38
Eczacybathorny-Monrol Collaborates with IBA 39
Safran Obtains EU Nod for GEHP Take Over 39
Siemens Healthcare Signs Agreement with Calypso Medical 39
IBA Molecular to Purchase Interest in BMI 40
Molecular Insight Signs Agreement with BioMedica Life Sciences 40
Bayer Schering Signs Agreement with Algeta 40
IBA Inks Agreement with Aposense 41
Draxis Receives Approval from Health Canada for Generic Sestamibi 41
Cyclopharm and Alfred Health Solutions Form Joint Venture 41
Guerbet Inks Distribution Agreement with Draximage 42
Ion Beam Applications Collaborates with Eczacibasi-Monrol
Nuclear Products 42
Positron Concludes Dose Shield Acquisition 43
Positron Licenses NuView to Sell Imaging Technologies and Dose
Dispensing Devices 43
Bracco Imaging, Marillion Pharmaceuticals to Develop Novel
Cancer Treatment 43
EUSA Pharma Concludes Cytogen Acquisition 43
AMIC, CRS to Co-Produce Indium-111 43
AMIC, MU Partner to Produce Radioisotopes 44
Bracco, Lantheus to Co-Promote CardioGen-82® 44
Cell Therapeutics Submits sBLA for Use of Zevalin® in First-
Line Therapy 44
ANSTO, Siemens Ink $10m Partnership Deal 44
Covidien Gets FDA Nod for Generic Myocardial Perfusion Imaging
Kit 44
Neoprobe, Draximage Collaborate Over Lymphoseek Distribution 45
GE Healthcare Gets FDA Nod For New PET/CT Scanner 45
GE Healthcare, Gamma Medica-Ideas Ink Distribution Deal 45
CIS-US Receives FDA Approval for Generic Choletec® Kit 45
Cellectar Obtains Funds for Clinical Trials 45
Lantheus Medical Completes Phase I Study Of Novel PET Imaging
Tracer 45
GE Healthcare, Cardinal Health Partner for Myoview™ Imaging Agent 46
Avista Capital Partners Acquires Medical Imaging Unit of
Bristol-Myers 46
Siemens Healthcare Opens Two Radiopharmacies in US 46
Cardinal Health Plans to Offer Services to Support PET
Clinical Trials 46
MEDRAD Associates with PETNET to Ingeniously Deliver FDG 47
Triad Isotopes to Build Four Nuclear Pharmacies 47
AREVA, NCI to Develop Cancer-fighting Radiopharmaceuticals 47
NuView Signs Agreement with California University 47
NuView Inks Exclusive Agreement with Philadelphia’s Jefferson
University 47
University of Missouri Health Care Enters Sole-Source Supply
Contract with Mid-America Isotopes 48
Cardinal Health Expands Manufacturing Capabilities for PET
Imaging Agents 48
Jubilant Completes Draxis Acquisition 48
Atomic Energy Closes Two Reactors 48
IBA Plans to Acquire CIS BIO 49
Ion Beam Announces Closure of TAEK Financing 49
IBA Receives Approval for New Radiopharmaceutical Production
Facility in UK 49
WILEX AG Signs Licensing and Marketing Deal with Ion Beam 49
Ion Beam Partners with Lantheus to Distribute Neurolite®,
Cardiolite® in Europe 50
EIS Eczacibasi to Acquire 50 Percent Stake in Monrol 50
Siemens to Set up Multiple Radiopharmaceutical Facilities in
India 50
Siemens Plans to Establish Its First Molecular Imaging Centre
in India 51
Ion Beam, Hae Dong Expands South Korea’s PET
Radiopharmaceutical Market 51
Bayer and FutureChem Enter Radiolabeling Technology Licensing
Agreement 51
Cyclopharm Signs Agreement to Establish PET Radiopharmacy 52
R2 Solucoes to Produce FGD-18, Radiological Diagnostics 52

6. FOCUS ON SELECT PLAYERS 53
Actinium Pharmaceuticals, Inc. (US) 53
Advanced Medical Isotope Corporation (US) 53
Alseres Pharmaceuticals, Inc (US) 53
Bayer HealthCare Pharmaceuticals (US) 54
Bio-Nucleonics, Inc. (US) 54
Bracco Diagnostics, Inc. (US) 54
Cardinal Health, Inc (US) 55
Covidien Imaging Solutions (US) 55
EUSA Pharma (Europe) Ltd. (UK) 55
Jubilant DraxImage Inc. (Canada) 55
GE Healthcare Limited (UK) 56
GlaxoSmithKline Plc (UK) 56
IBA Group (US) 56
Immunomedics, Inc. (US) 57
Lantheus Medical Imaging, Inc (US) 57
Nordion (Canada) 57
Molecular Insight Pharmaceuticals, Inc. (US) 58
Novelos Therapeutics Inc (US) 58
Peregrine Pharmaceuticals, Inc. (US) 58
PETNET Pharmaceuticals, Inc. (US) 59
Pharmalucence, Inc. (US) 59
Spectrum Pharmaceuticals, Inc. (USA) 59
Triad Isotopes, Inc. (US) 59

7. GLOBAL MARKET PERSPECTIVE 61
Table 4: World Recent Past, Current & Future Analysis for
Radiopharmaceuticals by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 61

Table 5: World Historic Review for Radiopharmaceuticals by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) 62

Table 6: World 15-Year Perspective for Radiopharmaceuticals by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Markets for 2003, 2010 & 2017 (includes
corresponding Graph/Chart) 63

Table 7: World Recent Past, Current & Future Analysis for
Diagnostic Radiopharmaceuticals by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) 64

Table 8: World Historic Review for Diagnostic
Radiopharmaceuticals by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) 65

Table 9: World 15-Year Perspective for Diagnostic
Radiopharmaceuticals by Geographic Region - Percentage
Breakdown of Value Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Rest of World Markets for
2003, 2010 & 2017 (includes corresponding Graph/Chart) 66

Table 10: World Recent Past, Current & Future Analysis for
Therapeutic Radiopharmaceuticals by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) 67

Table 11: World Historic Review for Therapeutic
Radiopharmaceuticals by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) 68

Table 12: World 15-Year Perspective for Therapeutic
Radiopharmaceuticals by Geographic Region - Percentage
Breakdown of Value Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Rest of World Markets for
2003, 2010 & 2017 (includes corresponding Graph/Chart) 69

8. THE UNITED STATES 70
A.Market Analysis 70
Outlook 70
Industry Structure 70
Production Scenario 70
Dependence On Imports 70
Regulatory Scenario 71
Thorny Regulations Dampen Down New Product Development 71
FDA’s Antidote 72
Radiopharmaceutical Reimbursement in the US: Who’s Under
the Umbrella 72
Diagnostic Radiopharmaceuticals Bundled As Supplies Under
Medicare Reimbursements 72
CMS Proposed Packaging of Zevalin & Bexxar into Diagnostic
Radiopharmaceuticals Raises Eyebrows 72
Implications 73
Recommendations 73
Changes in Medicare Reimbursements Vetoed 74
CMS Proposes New HOPPS Guidelines for 2012 74
(i) Reimbursement Rates for Nuclear Cardiology Procedures: 74
(ii) Reimbursement Rates for Radiopharmaceuticals 75
HOPPS Final Rule for 2011 75
(i) Reimbursement Rates for PET Imaging 75
(ii) Reimbursement Rates for Radiopharmaceuticals 76
HOPPS Guidelines for 2008 76
(i) Bundling Radiology Drugs and Services 76
(ii) Payment for Therapeutic Radiopharmaceuticals 77
(iii) PET/CT scans 78
(iv) Cardiac CT and Coronary CTA Procedures 78
(v) Conversion factor 78
Reimbursement Issues for PET 78
PET Clinical Applications Reimbursed by CMS as of March 2008 79
Deficit Reduction Act (DRA) 2005: Creating a Storm in a Teacup 79
Impact of the DRA On Outpatient Imaging Centers: An
Evaluation 80
Market Overview 81
Sanguine Growth On Cards 81
Expanding Diagnostic Applications Will Stimulate Future Growth 81
Nuclear Cardiology Products Drive Up Diagnostic
Radiopharmaceuticals Market 82
Cardiovascular Imaging To Lead Volume Growth 82
Cardiolite Loses Market Share to Generics 82
Table 13: US Diagnostic Radiopharmaceutical Agents Market
(2010): Percentage Share Breakdown of Procedure Volume by
Imaging Procedure - SPECT and PET (includes corresponding
Graph/Chart) 83

Table 14: US Market for Diagnostic Radiopharmaceuticals
Agents (2012): Percentage Share Breakdown of Value Sales
for Cardiology and Non-Cardiology Applications (includes
corresponding Graph/Chart) 83

Table 15: US Market for Cardiology Diagnostic
Radiopharmaceuticals (2010): Percentage Share Breakdown of
SPECT Myocardial Perfusion Imaging (MPI) Procedure Volume
by Imaging Agent - Cardiolite, Myoview, Thallium, and
Sestamibi (includes corresponding Graph/Chart) 84
New Oncology, Neurology Agents to Boost Diagnostic
Radiopharmaceuticals Market 84
Table 16: US Market for Non-Cardiology Diagnostic
Radiopharmaceuticals Agents (2010): Percentage Share
Breakdown of Value Sales for Oncology and Non-Oncology
Applications (includes corresponding Graph/Chart) 85
Installed Base of SPECT Scanners 85
Table 17: Diagnostic Radiopharmaceutical Market in North
America: Installed Base for SPECT and SPECT/CT Scanners in
Units for Years 2006, 2008, 2010, 2012 & 2014 (includes
corresponding Graph/Chart) 85
Installed Pet Scanners in US 86
US FDG Market 86
Table 18: US FDG Market (2010): Percentage Share Breakdown
of Procedure Volume by Procedure Type - Oncology,
Neurology and Cardiology (includes corresponding
Graph/Chart) 86
Focused R&D Efforts will Fuel Therapeutic
Radiopharmaceuticals Market 87
Market Share Statistics 87
Table 19: US Market for Diagnostics Radiopharmaceuticals
Agents (2010): Percentage Market Share Breakdown of Leading
Players (includes corresponding Graph/Chart) 87

Table 20: US Market for Therapeutic Radiopharmaceuticals
(2010): Percentage Share Breakdown of Value Sales by Key
Radiotherapeutics - Bone Palliation, Non-Hodgkin's
Lymphoma, Hyperthyroidism /Thyroid Cancer and Others
(includes corresponding Graph/Chart) 88

Table 21: US Market for Therapeutic Radiopharmaceutical
Agents (2010): Percentage Market Share Breakdown of Leading
Players (includes corresponding Graph/Chart) 88

Table 22: US Market for Radiopharmaceutical Bone Palliation
Procedures (2010): Percentage Share Breakdown by Key
Radiotherapeutics - Metastron, Quadramet and Sr-89
(includes corresponding Graph/Chart) 88

Table 23: Radiopharmacy Market in the US (2010): Percentage
Breakdown of Revenues Generated by General Radiopharmacies
and FDG Radiopharmacies (includes corresponding
Graph/Chart) 89
Product Launches 89
Strategic Corporate Developments 91
Select Players 99
B.Market Analytics 106
Table 24: US Recent Past, Current & Future Analysis for
Radiopharmaceuticals by Product Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 106

Table 25: US Historic Review for Radiopharmaceuticals for
Radiopharmaceuticals by Product Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) 107

Table 26: US 15-Year Perspective for Radiopharmaceuticals by
Product Segment - Percentage Breakdown of Value Sales for
Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes
corresponding Graph/Chart) 108

9. CANADA 109
A.Market Analysis 109
Outlook 109
Strategic Corporate Developments 109
Select Players 110
B.Market Analytics 111
Table 27: Canadian Recent Past, Current & Future Analysis
for Radiopharmaceuticals by Product Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 111

Table 28: Canadian Historic Review for Radiopharmaceuticals
by Product Segment - Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) 112

Table 29: Canadian 15-Year Perspective for
Radiopharmaceuticals by Product Segment - Percentage
Breakdown of Value Sales for Diagnostic Radiopharmaceuticals
and Therapeutic Radiopharmaceuticals for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 113

10. JAPAN 114
Market Analysis 114
Table 30: Japanese Recent Past, Current & Future Analysis
for Radiopharmaceuticals by Product Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 114

Table 31: Japanese Historic Review for Radiopharmaceuticals
by Product Segment - Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) 115

Table 32: Japanese 15-Year Perspective for
Radiopharmaceuticals by Product Segment - Percentage
Breakdown of Value Sales for Diagnostic Radiopharmaceuticals
and Therapeutic Radiopharmaceuticals for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 116

11. EUROPE 117
A.Market Analysis 117
Outlook 117
Competitive Scenario 117
Key Statistics 117
Table 33: European Radiopharmaceuticals Market (2010):
Percentage Share Breakdown of Revenues by Company (includes
corresponding Graph/Chart) 117

Table 34: European Diagnostic Radiopharmaceuticals Market
(2012): Percentage Share Breakdown of Value Sales by
Imaging Modalities - SPECT and PET (includes corresponding
Graph/Chart) 118
Market Trends 118
New Applications and Products Augur Good Market Prospects 118
Increasing PET and PET/CT Applications Will Kindle Growth 118
B.Market Analytics 119
Table 35: European Recent Past, Current & Future Analysis
for Radiopharmaceuticals by Geographic Region - France,
Germany, Italy, UK, Spain, and Rest of Europe Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) 119

Table 36: European Historic Review for Radiopharmaceuticals
by Geographic Region - France, Germany, Italy, UK, Spain,
and Rest of Europe Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 120

Table 37: European Recent Past, Current & Future Analysis
for Radiopharmaceuticals by Product Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 121

Table 38: European Historic Review for Radiopharmaceuticals
by Product Segment - Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) 122

Table 39: European 15-Year Perspective for
Radiopharmaceuticals by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK,
Spain, and Rest of Europe Markets for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 123

Table 40: European 15-Year Perspective for
Radiopharmaceuticals by Product Segment - Percentage
Breakdown of Value Sales for Diagnostic Radiopharmaceuticals
and Therapeutic Radiopharmaceuticals for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 124

11a. France 125
A.Market Analysis 125
Outlook 125
Strategic Corporate Development 125
B.Market Analytics 126
Table 41: French Recent Past, Current & Future Analysis for
Radiopharmaceuticals by Product Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 126

Table 42: French Historic Review for Radiopharmaceuticals by
Product Segment - Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) 127

Table 43: French 15-Year Perspective for
Radiopharmaceuticals by Product Segment - Percentage
Breakdown of Value Sales for Diagnostic Radiopharmaceuticals
and Therapeutic Radiopharmaceuticals for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 128

11b. Germany 129
A.Market Analysis 129
Outlook 129
Strategic Corporate Development 129
B.Market Analytics 130
Table 44: German Recent Past, Current & Future Analysis for
Radiopharmaceuticals by Product Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 130

Table 45: German Historic Review for Radiopharmaceuticals by
Product Segment - Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) 131

Table 46: German 15-Year Perspective for
Radiopharmaceuticals by Product Segment - Percentage
Breakdown of Value Sales for Diagnostic Radiopharmaceuticals
and Therapeutic Radiopharmaceuticals for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 132

11c. Italy 133
A.Market Analysis 133
Outlook 133
B.Market Analytics 133
Table 47: Italian Recent Past, Current & Future Analysis for
Radiopharmaceuticals by Product Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 133

Table 48: Italian Historic Review for Radiopharmaceuticals
by Product Segment - Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) 134

Table 49: Italian 15-Year Perspective for
Radiopharmaceuticals by Product Segment - Percentage
Breakdown of Value Sales for Diagnostic Radiopharmaceuticals
and Therapeutic Radiopharmaceuticals for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 135

11d. The United Kingdom 136
A.Market Analysis 136
Outlook 136
Market Overview 136
Strategic Corporate Developments 136
Select Players 137
B.Market Analytics 138
Table 50: UK Recent Past, Current & Future Analysis for
Radiopharmaceuticals by Product Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 138

Table 51: UK Historic Review for Radiopharmaceuticals by
Product Segment - Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) 139

Table 52: UK 15-Year Perspective for Radiopharmaceuticals by
Product Segment - Percentage Breakdown of Value Sales for
Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes
corresponding Graph/Chart) 140

11e. Spain 141
Market Analysis 141
Table 53: Spanish Recent Past, Current & Future Analysis for
Radiopharmaceuticals by Product Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 141

Table 54: Spanish Historic Review for Radiopharmaceuticals
by Product Segment - Diagnostic Radiopharmaceuticals and
Therapeutic Radiopharmaceuticals Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) 142

Table 55: Spanish 15-Year Perspective for
Radiopharmaceuticals by Product Segment - Percentage
Breakdown of Value Sales for Diagnostic Radiopharmaceuticals
and Therapeutic Radiopharmaceuticals for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 143

11f. Rest of Europe 144
A.Market Analysis 144
Outlook 144
Market Overview 144
Product Launches 144
Strategic Corporate Developments 145
B.Market Analytics 154
Table 56: Rest of Europe Recent Past, Current & Future
Analysis for Radiopharmaceuticals by Product Segment -
Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) 154

Table 57: Rest of Europe Historic Review for
Radiopharmaceuticals by Product Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) 155

Table 58: Rest of Europe 15-Year Perspective for
Radiopharmaceuticals by Product Segment - Percentage
Breakdown of Value Sales for Diagnostic Radiopharmaceuticals
and Therapeutic Radiopharmaceuticals for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 156

12. ASIA-PACIFIC 157
A.Market Analysis 157
Outlook 157
Product Launch 157
Strategic Corporate Developments 157
B.Market Analytics 161
Table 59: Asia-Pacific Recent Past, Current & Future
Analysis for Radiopharmaceuticals by Product Segment -
Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) 161

Table 60: Asia-Pacific Historic Review for
Radiopharmaceuticals by Product Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) 162

Table 61: Asia-Pacific 15-Year Perspective for
Radiopharmaceuticals by Product Segment - Percentage
Breakdown of Value Sales for Diagnostic Radiopharmaceuticals
and Therapeutic Radiopharmaceuticals for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 163

13. REST OF WORLD 164
A.Market Analysis 164
Outlook 164
Strategic Corporate Developments 164
B.Market Analytics 165
Table 62: Rest of World Recent Past, Current & Future
Analysis for Radiopharmaceuticals by Product Segment -
Diagnostic Radiopharmaceuticals and Therapeutic
Radiopharmaceuticals Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) 165

Table 63: Rest of World Historic Review for
Radiopharmaceuticals by Product Segment - Diagnostic
Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) 166

Table 64: Rest of World 15-Year Perspective for
Radiopharmaceuticals by Product Segment - Percentage
Breakdown of Value Sales for Diagnostic Radiopharmaceuticals
and Therapeutic Radiopharmaceuticals for Years 2003, 2010 &
2017 (includes corresponding Graph/Chart) 167


COMPETITIVE LANDSCAPE

Total Companies Profiled: 65 (including Divisions/Subsidiaries - 79)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 40
Canada 3
Japan 1
Europe 27
France 1
Germany 6
The United Kingdom 4
Italy 2
Spain 1
Rest of Europe 13
Asia-Pacific (Excluding Japan) 6
Africa 1
Middle-East 1
------------------------------------------